间苯三酚三甲醚主要用于制备间苯三酚注射液，其主要用于治疗消化系统和胆道功能障碍引起的急性痉 挛疼痛;急性痉挛性尿道、膀胱、肾绞痛;及妇科痉挛性疼痛。诚如本公司日期为2024年8月27日的公告 所载，本集团已取得国家药监局有关间苯三酚注射液的药品生产注册批件。 盐酸多巴酚丁胺主要用于制备盐酸多巴酚丁胺注射液，其主要用于器质性心脏病时心肌收缩力下降引起 的心力衰竭，包括心脏直视手术后所致的低排血量综合症。 石四药集团(02005)发布公告，本集团的间苯三酚三甲醚及盐酸多巴酚丁胺已获中国国家药品监督管理 局(国家药监局)批准登记成为在上市制剂使用的原料药。 ...

盐酸多巴酚丁胺主要用于制备盐酸多巴酚丁胺注射液，其主要用于器质性心脏病时心肌收缩力下降引起 的心力衰竭，包括心脏直视手术后所致的低排血量综合症。 间苯三酚三甲醚主要用于制备间苯三酚注射液，其主要用于治疗消化系统和胆道功能障碍引起的急性痉 挛疼痛;急性痉挛性尿道、膀胱、肾绞痛;及妇科痉挛性疼痛。诚如本公司日期为2024年8月27日的公告 所载，本集团已取得国家药监局有关间苯三酚注射液的药品生产注册批件。 智通财经APP讯，石四药集团(02005)发布公告，本集团的间苯三酚三甲醚及盐酸多巴酚丁胺已获中国国 家药品监督管理局(国家药监局)批准登记成为在上市制剂使用的原料药。 ...

间苯三酚三甲醚主要用于制备间苯三酚注射液，其主要用于治疗(i)消化系统和胆道功能障碍引起的急性 痉挛疼痛；(ii)急性痉挛性尿道、膀胱、肾绞痛；及(iii)妇科痉挛性疼痛。集团已取得国家药监局有关间 苯三酚注射液的药品生产注册批件。 格隆汇2月9日丨石四药集团(02005.HK)公告，集团的间苯三酚三甲醚及盐酸多巴酚丁胺已获中国国家药 品监督管理局("国家药监局")批准登记成为在上市制剂使用的原料药。 盐酸多巴酚丁胺主要用于制备盐酸多巴酚丁胺注射液，其主要用于器质性心脏病时心肌收缩力下降引起 的心力衰竭，包括心脏直视手术后所致的低排血量综合症。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的間苯三酚三甲醚及鹽酸多巴酚丁胺已獲中國國家藥品監督管理局（「國家藥監局」）批 准登記成為在上市製劑使用的原料藥。 間苯三酚三甲醚主要用於製備間苯三酚注射液，其主要用於治療(i)消化系統和膽道功能障礙引 起的急性痙攣疼痛；(ii)急性痙攣性尿道、膀胱、腎絞痛；及(iii)婦科痙攣性疼痛。誠如本公司 日期為二零二四年八月二十七日之公告所載，本集團已取得國家藥監局有關間苯三酚注射液的 藥品生產註冊批件。 鹽酸多巴酚丁胺主要用於製備鹽酸多巴酚丁胺注射液，其主要用於器質性心臟病時心肌收縮力 下降引起的心力衰竭，包括心臟直視手術後所致的低排血量綜合症。 自願公告 產品開發的最新進展 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年 ...

Core Viewpoint - Xinhua Pharmaceutical has recently received drug registration certificates for two new products, which are expected to enhance its market competitiveness and revenue potential in the coming year [2][3]. Group 1: Stock Performance - As of December 31, 2025, Xinhua Pharmaceutical's stock closed at 15.41 yuan, down 2.53% from the previous week's 15.81 yuan [1]. - The stock reached a high of 15.85 yuan and a low of 15.40 yuan during the week [1]. - The company's current total market capitalization is 10.629 billion yuan, ranking 49th out of 150 in the chemical pharmaceutical sector and 1817th out of 5181 in the A-share market [1]. Group 2: Product Approvals - Xinhua Pharmaceutical has obtained a drug registration certificate for isopropyl phenol injection, classified as a Class 4 chemical drug, aimed at treating spasmodic pain in the digestive, biliary, urinary, and gynecological systems, with an expected sales revenue of approximately 900 million yuan in 2024 for public medical institutions [2][3]. - The company has also received a registration certificate for valsartan capsules, also classified as a Class 4 chemical drug, intended for the treatment of mild to moderate primary hypertension, with an anticipated sales revenue of about 1.82 billion yuan in 2024 for public medical institutions [2][3]. - The approval of these two products is expected to enhance the company's product competitiveness, although sales may be influenced by policy and market factors, introducing some uncertainty [2].

Group 1 - Nan Mining Group signed a procurement contract for iron ore equipment worth 3 billion yuan with Lanyan Weiye Mineral Processing Co., Ltd., for a project processing over 4.6 million tons of ore annually, with an estimated operational cost of 3 billion yuan over 10 years [1] - Guangdong Yuedian A's Dapu Power Plant Phase II Project's Unit 4 has commenced commercial operation, with a total investment of 8.122 billion yuan and an expected annual power generation of 9 billion kilowatt-hours [2] - China Energy Engineering's subsidiary won an EPC general contracting project in Shaanxi Province with a bid amount of approximately 6.864 billion yuan, covering ecological governance, infrastructure, urban renewal, and water conservancy projects, with a total construction period of 36 months [3] Group 2 - ST Dongtong's stock will resume trading on December 30, 2025, entering a delisting arrangement period of 15 trading days, with the last trading date expected to be January 21, 2026 [4] - Roman Co.'s subsidiary signed a contract for a computing power service project worth approximately 156 million yuan with Tianjin Maoyuan Equipment Leasing Co., Ltd. and China Merchants Intelligent Supply Chain Service Co., Ltd. [5] - Hangzhou Thermal Power plans to sign a three-year coal purchase contract with Shanghai Yitai Shenpu for a total of 9 million tons, ensuring stable coal supply from 2026 to 2028 [6] Group 3 - Caitong Securities received approval from the China Securities Regulatory Commission to publicly issue bonds totaling no more than 15 billion yuan [7] - Qipai Technology's application for a stock issuance to specific investors has been approved by the Shanghai Stock Exchange [8] - China Software plans to sell 555 units of X86 servers and two properties to optimize idle assets, with a total estimated value of approximately 6.758 million yuan [10] Group 4 - Xinhua Medical received medical device registration certificates for two products, including an interleukin-6 test kit and a dual test kit for procalcitonin/interleukin-6 [11] - Shandong Haohua announced the resignation of Deputy General Manager Yuan Falin due to personal reasons [12] - Haixiang Pharmaceutical's invested company NWRD06 injection has completed the enrollment of the first subject in its Phase II clinical trial [13] Group 5 - Tiantong Co. terminated the absorption merger of its wholly-owned subsidiary Tiantong Rijing Precision Technology Co., Ltd., retaining its independent legal status [14] - Ruima Precision's subsidiary received a project designation for automotive air suspension systems, with an estimated sales revenue of approximately 1.342 billion yuan over a six-year lifecycle [15] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Qianxing Future to enhance collaboration in the development and manufacturing of quadruped robots [16] Group 6 - Huali Co. terminated the acquisition of a 51% stake in Zhongke Huilian due to failure to reach consensus on key transaction terms [17] - Acolyte's olefin copolymer has passed customer verification and is now in bulk supply for the optical lens sector [18] - Tianjian Technology signed a supplementary agreement for military product price adjustments, expecting a revenue reduction of approximately 256 million yuan [19] Group 7 - Southeast Network Framework won an EPC project bid for the "China Vision Valley Industrial Base" with a total bid amount of 888 million yuan [20] - Baodi Mining plans to acquire 87% of Congling Energy for a total of 685 million yuan through a combination of cash and share issuance [21] - Heng Rui Pharmaceutical received clinical trial approval for multiple drugs, including HRS-6257 tablets for treating acute and chronic pain [22] Group 8 - Zhongxin Saike received a dividend of 60 million yuan from its wholly-owned subsidiary [23] - ST Songfa's subsidiary signed a contract for the construction of an oil tanker with a total contract value of approximately 80 to 100 million USD [24] - China Resources Double Crane received clinical trial approval for hydroxocobalamin injection, aimed at treating metabolic disorders in children [25][26]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the injection of phenobarbital, which is intended for the treatment of acute spasmodic pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1] Company Summary - Xinhua Pharmaceutical has obtained the drug registration certificate for the injection of phenobarbital, indicating a significant regulatory milestone for the company [1]

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the registration certificates of Valsartan capsules and Isosorbide Injection, indicating a significant advancement in its product offerings and potential market expansion [1] Group 1: Product Approvals - Valsartan capsules are indicated for the treatment of mild to moderate primary hypertension [1] - Isosorbide Injection is used for treating acute spasmodic pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration certificate of its injection product, Benzyl Alcohol Injection, which is intended for treating acute spasmodic pain caused by digestive system and biliary dysfunction, as well as acute spasmodic pain in the urinary tract, bladder, and kidney, and gynecological spasmodic pain [1] Company Summary - The company has announced the approval of Benzyl Alcohol Injection, which expands its product offerings in the pharmaceutical market [1] - This product is specifically designed to address various types of acute spasmodic pain, indicating a focus on pain management solutions [1] Industry Summary - The approval of new pharmaceutical products like Benzyl Alcohol Injection reflects ongoing developments in the healthcare sector, particularly in pain management therapies [1] - The market for treatments addressing acute spasmodic pain is significant, highlighting potential growth opportunities for companies in this segment [1]

Group 1 - The core point of the article is that Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of its injection product, Isopropylphenol [1] - The product is indicated for the treatment of acute spasmodic pain caused by digestive system and biliary dysfunction, as well as acute spasmodic pain in the urinary tract, bladder, and kidney, and gynecological spasmodic pain [1] - The product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] Group 2 - In July 2024, the company submitted the registration application for the domestic production of Isopropylphenol injection, which was accepted by the National Medical Products Administration [1] - The product received its registration certificate in December 2025, with the review conclusion being approval for registration [1] - The estimated sales revenue for Isopropylphenol injection in Chinese public medical institutions is approximately RMB 900 million in 2024 [1]